1. Pink Sheet
  2. >>Geography
  3. >>North America

Salonpas Ad Claims Pass FTC Test After Firm Refuses NAD Review

 
• By Elizabeth Crawford

NAD cases do not go to FTC with a guarantee of enforcement, but firms should not ignore NAD requests for substantiation. FTC declined to enforce against Hisamitsu’s claims for Salonpas OTC pain relief patches after the firm declined to provide information for a NAD review prompted by a Pfizer challenge.

OTC drug and nutritional product firms should not see an invitation to ignore the National Advertising Division without consequences in the Federal Trade Commission decision not to enforce against Hisamitsu Pharmaceutical Co. Inc. after NAD referred the firm’s Salonpas advertising to the agency.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America